📊 TENX Key Takeaways
Is Tenax Therapeutics, Inc.. (TENX) a Good Investment?
Tenax is a pre-revenue pharmaceutical company with exceptional financial health ($118.8M cash, $114.7M equity, zero debt) providing 12+ years of operational runway. However, the absence of any revenue, significant operating losses (-$16.6M), negative free cash flow (-$9.3M), and deteriorating EPS (-16.5% YoY) indicate a development-stage company purely dependent on undisclosed pipeline success. Pure fundamental metrics show value destruction without demonstrated clinical or commercial progress.
Tenax Therapeutics, Inc.. Key Strengths (TENX)
- Fortress balance sheet with $118.8M cash and zero debt eliminates near-term financial distress risk
- Exceptionally strong liquidity (14.52x current ratio) and extended operational runway (~12.8 years) provides flexibility for R&D execution
- Lean capital structure focused on R&D with minimal capex ($2.8K) appropriate for development-stage biotech
TENX Stock Risks: Tenax Therapeutics, Inc.. Investment Risks
- Zero revenue generation with significant operating losses (-$16.6M) and no demonstrated path to commercialization
- Negative free cash flow (-$9.3M annually) with deteriorating EPS (-16.5% YoY) indicates mounting losses eroding shareholder value
- Pharmaceutical development risk is inherent; clinical trial success probability is unknown from financial fundamentals alone; extended cash burn could exhaust runway if pipeline fails
Key Metrics to Watch
- Operating cash burn rate and year-over-year burn trajectory acceleration or deceleration
- Revenue recognition milestone - first indicator of successful commercialization
- R&D spending efficiency and clinical milestone progression announcements
Tenax Therapeutics, Inc.. (TENX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.52x current ratio provides a solid financial cushion.
TENX Profit Margin, ROE & Profitability Analysis
TENX vs Healthcare Sector: How Tenax Therapeutics, Inc.. Compares
How Tenax Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tenax Therapeutics, Inc.. Stock Overvalued? TENX Valuation Analysis 2026
Based on fundamental analysis, Tenax Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tenax Therapeutics, Inc.. Balance Sheet: TENX Debt, Cash & Liquidity
TENX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tenax Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
TENX Revenue Growth, EPS Growth & YoY Performance
TENX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$10.4M | $-0.28 |
| Q3 2025 | N/A | -$3.6M | $-0.19 |
| Q2 2025 | N/A | -$3.6M | $-0.27 |
| Q1 2025 | N/A | -$3.8M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tenax Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
TENX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tenax Therapeutics, Inc.. (CIK: 0000034956)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TENX
What is the AI rating for TENX?
Tenax Therapeutics, Inc.. (TENX) has an AI grade of B with 35% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TENX's key strengths?
Claude: Fortress balance sheet with $118.8M cash and zero debt eliminates near-term financial distress risk. Exceptionally strong liquidity (14.52x current ratio) and extended operational runway (~12.8 years) provides flexibility for R&D execution.
What are the risks of investing in TENX?
Claude: Zero revenue generation with significant operating losses (-$16.6M) and no demonstrated path to commercialization. Negative free cash flow (-$9.3M annually) with deteriorating EPS (-16.5% YoY) indicates mounting losses eroding shareholder value.
What is TENX's revenue and growth?
Tenax Therapeutics, Inc.. reported revenue of $0.0.
Does TENX pay dividends?
Tenax Therapeutics, Inc.. does not currently pay dividends.
Where can I find TENX SEC filings?
Official SEC filings for Tenax Therapeutics, Inc.. (CIK: 0000034956) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TENX's EPS?
Tenax Therapeutics, Inc.. has a diluted EPS of $-0.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TENX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Tenax Therapeutics, Inc.. has a B grade with 35% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TENX stock overvalued or undervalued?
Valuation metrics for TENX: ROE of -13.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TENX's AI grade for 2026?
Our dual AI analysis gives Tenax Therapeutics, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TENX's free cash flow?
Tenax Therapeutics, Inc..'s operating cash flow is $-9.3M, with capital expenditures of $2.8K.
How does TENX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.7% (avg: 15%), current ratio 14.52 (avg: 2).